Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy

After an initial screening phase to identify patients with persistent blood circulating DNA tumors, patients will be enrolled in the treatment phase that was designed as an open-label, multicentre, phase II study, to test the efficacy of trastuzumab deruxtecan in terms of progression-free survival (PFS).

Trial Details

NCT ID
NCT06680596
Phase
PHASE2
Sponsor
UNICANCER
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • trastuzumab derxutecan
Locations (sample)
  • Amiens, France|49.9,2.3
  • Amiens, France|49.9,2.3
  • Auxerre, France|47.7996,3.57033
  • Avignon, France|43.94834,4.80892
  • Bayonne, France|43.49316,-1.473

Key Eligibility Criteria

  • Patient must have signed the written informed consent for screening phase prior to any trial specific procedures.
  • Note: When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or t…
  • Patient is ≥18 years of age.
  • Documented breast cancer that:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →